126 related articles for article (PubMed ID: 21109332)
1. 1,2,5-Oxadiazole analogues of leflunomide and related compounds.
Giorgis M; Lolli ML; Rolando B; Rao A; Tosco P; Chaurasia S; Marabello D; Fruttero R; Gasco A
Eur J Med Chem; 2011 Jan; 46(1):383-92. PubMed ID: 21109332
[TBL] [Abstract][Full Text] [Related]
2. New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold.
Lolli ML; Giorgis M; Tosco P; Foti A; Fruttero R; Gasco A
Eur J Med Chem; 2012 Mar; 49():102-9. PubMed ID: 22245049
[TBL] [Abstract][Full Text] [Related]
3. The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors.
Bonomo S; Tosco P; Giorgis M; Lolli M; Fruttero R
J Mol Model; 2013 Mar; 19(3):1099-107. PubMed ID: 23143678
[TBL] [Abstract][Full Text] [Related]
4. Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
Leban J; Vitt D
Arzneimittelforschung; 2011; 61(1):66-72. PubMed ID: 21355448
[TBL] [Abstract][Full Text] [Related]
5. 3D-QSAR studies on a series of dihydroorotate dehydrogenase inhibitors: analogues of the active metabolite of leflunomide.
Li SL; He MY; Du HG
Int J Mol Sci; 2011; 12(5):2982-93. PubMed ID: 21686163
[TBL] [Abstract][Full Text] [Related]
6. Biaryl analogues of teriflunomide as potent DHODH inhibitors.
Erra M; Moreno I; Sanahuja J; Andrés M; Reinoso RF; Lozoya E; Pizcueta P; Godessart N; Castro-Palomino JC
Bioorg Med Chem Lett; 2011 Dec; 21(24):7268-72. PubMed ID: 22078215
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of beta-hydroxy-propenamide derivatives and the inhibition of human dihydroorotate dehydrogenase.
Kim TH; Na HS; Löffler M
Arch Pharm Res; 2003 Mar; 26(3):197-201. PubMed ID: 12723931
[TBL] [Abstract][Full Text] [Related]
8. Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor.
Hurt DE; Widom J; Clardy J
Acta Crystallogr D Biol Crystallogr; 2006 Mar; 62(Pt 3):312-23. PubMed ID: 16510978
[TBL] [Abstract][Full Text] [Related]
9. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Hurt DE; Sutton AE; Clardy J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
[TBL] [Abstract][Full Text] [Related]
10. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures.
McLean LR; Zhang Y; Degnen W; Peppard J; Cabel D; Zou C; Tsay JT; Subramaniam A; Vaz RJ; Li Y
Bioorg Med Chem Lett; 2010 Mar; 20(6):1981-4. PubMed ID: 20153645
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds.
Kuo EA; Hambleton PT; Kay DP; Evans PL; Matharu SS; Little E; McDowall N; Jones CB; Hedgecock CJ; Yea CM; Chan AW; Hairsine PW; Ager IR; Tully WR; Williamson RA; Westwood R
J Med Chem; 1996 Nov; 39(23):4608-21. PubMed ID: 8917650
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase from Y strain.
Pinheiro MP; Iulek J; Cristina Nonato M
Biochem Biophys Res Commun; 2008 May; 369(3):812-7. PubMed ID: 18302934
[TBL] [Abstract][Full Text] [Related]
14. Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery.
Cheleski J; Rocha JR; Pinheiro MP; Wiggers HJ; da Silva AB; Nonato MC; Montanari CA
Eur J Med Chem; 2010 Dec; 45(12):5899-909. PubMed ID: 20965617
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive agent leflunomide: a SWNTs-immobilized dihydroortate dehydrogenase inhibitory effect and computational study of its adsorption properties on zigzag single walled (6,0) carbon and boron nitride nanotubes as controlled drug delivery devices.
Raissi H; Mollania F
Eur J Pharm Sci; 2014 Jun; 56():37-54. PubMed ID: 24566615
[TBL] [Abstract][Full Text] [Related]
17. Chemometric modeling, docking and in silico design of triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors as antimalarials.
Ojha PK; Roy K
Eur J Med Chem; 2010 Oct; 45(10):4645-56. PubMed ID: 20708304
[TBL] [Abstract][Full Text] [Related]
18. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
[TBL] [Abstract][Full Text] [Related]
19. The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Heikkilä T; Thirumalairajan S; Davies M; Parsons MR; McConkey AG; Fishwick CW; Johnson AP
Bioorg Med Chem Lett; 2006 Jan; 16(1):88-92. PubMed ID: 16236496
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases.
Bedingfield PT; Cowen D; Acklam P; Cunningham F; Parsons MR; McConkey GA; Fishwick CW; Johnson AP
J Med Chem; 2012 Jun; 55(12):5841-50. PubMed ID: 22621375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
